1. Home
  2. CFFN vs PHAT Comparison

CFFN vs PHAT Comparison

Compare CFFN & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capitol Federal Financial Inc.

CFFN

Capitol Federal Financial Inc.

HOLD

Current Price

$8.48

Market Cap

981.1M

Sector

Finance

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$10.72

Market Cap

894.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFFN
PHAT
Founded
1893
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
981.1M
894.0M
IPO Year
2010
2019

Fundamental Metrics

Financial Performance
Metric
CFFN
PHAT
Price
$8.48
$10.72
Analyst Decision
Hold
Strong Buy
Analyst Count
2
6
Target Price
$7.25
$19.83
AVG Volume (30 Days)
692.8K
1.0M
Earning Date
04-29-2026
04-30-2026
Dividend Yield
4.51%
N/A
EPS Growth
79.31
42.72
EPS
0.32
N/A
Revenue
$16,300,000.00
$175,110,000.00
Revenue This Year
$20.16
$93.04
Revenue Next Year
$6.62
$58.91
P/E Ratio
$26.44
N/A
Revenue Growth
6.54
216.93
52 Week Low
$5.71
$7.61
52 Week High
$8.49
$18.31

Technical Indicators

Market Signals
Indicator
CFFN
PHAT
Relative Strength Index (RSI) 65.29 47.96
Support Level $7.49 $10.02
Resistance Level N/A $11.65
Average True Range (ATR) 0.15 0.57
MACD 0.03 0.09
Stochastic Oscillator 78.26 48.49

Price Performance

Historical Comparison
CFFN
PHAT

About CFFN Capitol Federal Financial Inc.

Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: